Tagged Articles

Invokana 112 articles

SGLT2 inhibitor benefits come at a risk

A new class of diabetes drugs called SGLT2 inhibitors launched in the U.S. in 2013 are demonstrating they can effectively drive down blood sugar levels and even help users lose weight. But those benefits come at a risk, according to a speaker at the Cardiometabolic Health Congress. SGLT2 inhibitors, or sodium-glucose cotransporter 2 inhibitors, include the brand name drugs Invokana and Invokana (which contain the active ingredient canagliflozin); Farxiga and Xigduo XR (which contain the active ingredient dapagliflozin); and Jardiance (which contains the active ingredient empagliflozin). SGLT2 inhibitors lower blood sugar by causing the kidneys to remove the sugar from ... Read More

ESPN radio’s Mike Golic a paid spokesperson for diabetes drug Invokana

ESPN radio host Mike Golic with Mike and Mike in the Morning is now a paid spokesman for the type 2 diabetes drug Invokana. The former NFL defensive linebacker was diagnosed with the chronic disease a dozen years ago and has been on a mission to raise awareness about the condition. Mike said he remembers when his father was diagnosed with type 2 diabetes. Yet, he never believed he’d get the disease. His father kept mum about his struggles, but Mike wanted to be more open about his. “I wanted to be very proactive and involve my wife, involve my ... Read More

Global warming may lead to more cases of type 2 diabetes

There’s another reason to fear global warming. Not only does a mere 1 degree Celsius increase on average raise sea levels, lower crop yields and shrink habitats for vulnerable species, a new study suggests that an additional 100,000 people could develop diabetes as a result of climate change. Climate control experts previously warned that such changes in the world’s temperatures could lead to the spread of conditions like as mosquito-born malaria and dengue fever. It could also lead to the spread of water-borne illnesses like cholera. Diabetes is a breed of its own. The chronic condition isn’t contagious, but those ... Read More

National Kidney Month: Some medications linked to acute kidney injury

March is National Kidney Month is an awareness campaign that should be important to people with type 2 diabetes. That is because diabetes is the leading cause of kidney failure, the last stage of kidney disease in which the kidneys fail to filter impurities from the blood, requiring kidney transplantation or dialysis. Many conditions, diseases and medicines can create situations that lead to acute and chronic kidney disease that can lead to kidney failure. Chronic kidney disease (CKD) is usually caused by a long-term disease like diabetes or high blood pressure that slowly damages the kidneys and reduces function over ... Read More

Plaintiffs ask judge not to transfer Invokana side effects lawsuits to NJ

More than 100 people suing Johnson & Johnson and Janssen Pharmaceuticals over kidney damage allegedly caused by the companies’ diabetes drug Invokana are asking a Pennsylvania federal judge not to transfer their cases to a recently established multidistrict litigation (MDL) in New Jersey, arguing doing so would go against common logic. Johnson & Johnson and its unit Janssen filed a motion last November to stay and transfer or dismiss 106 of the 143 cases that had been filed in Pennsylvania Court of Common Pleas and later removed to the U.S. District Court for the Eastern District of Pennsylvania. Plaintiffs argue ... Read More

J&J hopes to lure new users to diabetes drug despite Invokana side effects

It’s not enough that the type 2 diabetes drug is a blockbuster, nabbing more than $1 billion in sales in 2015 despite a growing list of side effects. Its makers, Johnson & Johnson and subsidiary Janssen Pharmaceuticals, hope to draw users by promoting the drug as a tool to help reduce cardiac events. Later this year, Johnson & Johnson and Janssen will be armed with results from a seven-year study called CANVAS looking at the drug’s impact on the heart health of about 4,300 patients. If that data is favorable, the companies will likely ask the Food and Drug Administration ... Read More

Top FDA Safety Alerts for 2016

The Food and Drug Administration (FDA) issued Safety Alerts for 60 drugs or therapeutic biological products during 2016. Here are some of the most notable safety issues: April 5 – Type 2 diabetes medications containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease, the FDA warned. Brand-name drugs listed in this warning include Onglyza, Kombiglyze XR, Nesnia, Kazano, and Oseni. May 3 – A number of cases of compulsive or uncontrollable urges to gamble, binge eat, shop and have sex were reported with the antipsychotic drug aripiprazole resulting ... Read More

Docs paid more to promote Invokana than any other diabetes med

Doctors were paid a total of $20.9 million in 2015 to promote Invokana – millions more than any other type 2 diabetes medication, according to ProPublica’s updated Dollars for Docs database. The money covered so-called “general payments” involving fees, meals, travel, gifts and royalties to health care providers for promotional speeches or consulting related to Invokana. The payments do not include research. Diabetes is a growing epidemic in the United States. About 29.1 million Americans have been diagnosed with the chronic condition. People with diabetes must follow a lifelong strict diet and monitor their blood sugar daily. Many rely on ... Read More

Number of lawsuits in Invokana MDL expected to grow

Fifty-five lawsuits alleging the type 2 diabetes drug Invokana caused health risks were consolidated in New Jersey federal court Dec. 8 by the Judicial Panel for Multidistrict Litigation, and that number is expected to grow. The panel says it expects an additional 44 cases to be filed in the U.S. District court for the District of New Jersey, transferred from districts in Minnesota, Illinois, Kentucky, Missouri, Virginia and West Virginia. The lawsuits target Invokana makers Johnson & Johnson subsidiary Janssen Pharmaceuticals and Mitsubishi Tanabe Pharmaceuticals, claiming the drug companies failed to warn doctors or patients of the risks associated with ... Read More

Benefits of SGLT2 diabetes drugs should be weighed against side effects

The Food and Drug Administration (FDA) has signed off on a new indication for the type 2 diabetes drug Jardiance, allowing its manufacturers Eli Lily and Boehringer Ingelheim to advertise that the medication can reduce the risk of cardiovascular death in type 2 diabetics. The new indication is expected not only to boost sales of Jardiance, but also sales of other diabetes treatments in its class. Jardiance is in a newer class of drugs called SGLT2 inhibitors. Johnson & Johnson and Janssen Pharmaceuticals’ Invokana was the first in the class to be approved and enjoys the largest sales among its direct ... Read More